In the current investigation, Tuberculosis remains a formidable global health challenge, necessitating innovative approaches for effective treatment. Current study attempted to identify potential pyridyltriazole derivatives for Mtbenoyl-reductaseInhA inhibition from virtually designed ligand library. Molecular docking study was utilized for identification of hits against selected molecular target. This in silico study delved into the molecular interactions between potential compounds and the Mtbenoyl-reductaseInhA (PDB 5JFO). Furthermore, research utilising molecular docking have been conducted to get mechanistic understanding and molecular interactions in opposition to the mycobacterial InhA enzyme. Utilising a molecular docking analysis, hits against specific molecular targets were found. Compound 21 emerged with the highest negative binding affinity (-10.2kcal/mol) further followed closely by compound 5 (--10.1 kcal/mol) and found exhibiting promising interactions within the active site of enoyl-reductaseInhA. According to the In-silico ADME prediction, every designed molecule has drug-like qualities and is appropriate for oral bioavailability. These findings emphasize the potential of these compounds as inhibitors and place the footing for further optimization to develop more potent anti-TB therapeutics.